GLOBUS MEDICAL INC
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Other Information
On June 7, 2024, Daniel T. Scavilla, President and Chief Executive Officer, adopted a Rule 10b5-1 Trading Plan. Mr. Scavilla’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of August 31, 2025 or the sale of all shares subject to the plan, provides for the sale of up to 190,000 shares of Class A common stock pursuant to the terms of the plan.
On June 13, 2024, Kelly G. Huller, Senior Vice President and General Counsel, adopted a Rule 10b5-1 Trading Plan. Ms. Huller’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of January 31, 2026 or the sale of all shares subject to the plan, provides for the sale of up to 15,000 shares of Class A common stock pursuant to the terms of the plan.
Item 6.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.